Vaxcyte Inc. (PCVX) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Vaxcyte Inc. (NASDAQ: PCVX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $62.03 (-0.93% 1D, market cap $9.85B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, PCVX ranks #303 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PCVX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.6%. By comparison, KRYS (Krystal Biotech Inc.) holds a B grade (72/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.61B) and KYMR (Kymera Therapeutics Inc.) posts a D grade (50/100 RQD, P/E 32.7x, ROIC -21.4%, cap $10.19B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
Per PCVX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649094), Vaxcyte Inc. generated $0 in revenue, -$766.6K in net income, and -$669.3M in free cash flow against $3.00B in total assets and $142.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 18.11 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
20D Institutional Volume Accumulation (±10.7% realized swing band)
Capital intensity & 0% operating margin leave 15 pts on the table
While PCVX currently carries a cautious 49/100 (D) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Clean SEC annual filing review with no major hidden accounting time-bombs.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($61.62) and Max Pain ($65.13) forces dealer call-delta covering toward $95.29.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Vaxcyte Inc. (PCVX) slipped -0.93% to $62.03, trading at 44% of its 52-week range ($39.87 – $90.75). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earning
Vaxcyte is a late clinical-stage vaccine company positioned as a potential disruptor in the vaccine market. Learn more about PCVX stock here.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PCVX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PCVX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Vaxcyte Inc. (PCVX) ranks #303 by composite RQD confidence (49/100, grade D) and #115 by equity capitalization ($9.85B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PCVX at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PCVX
ACTIVE
Vaxcyte Inc. | D | 49/100 | — | — | -27.6% | -0.93% | $9.85B | Benchmark Subject |
| KRYS Krystal Biotech Inc. | B | 72/100 | 46.9x | — | 16.5% | +2.38% | $9.61B | /krys-vs-pcvx → |
| KYMR Kymera Therapeutics Inc. | D | 50/100 | 32.7x | — | -21.4% | +3.29% | $10.19B | /kymr-vs-pcvx → |
| QGEN Qiagen N.V. | B- | 71/100 | 24.4x | 62.2% | 8.0% | -0.24% | $10.37B | /qgen-vs-pcvx → |
| IBRX ImmunityBio Inc. | D- | 37/100 | — | 96.0% | -27.3% | -5.15% | $9.26B | /ibrx-vs-pcvx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vaxcyte Inc. (PCVX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$766.6K, operating cash flow of -$655.6M, and free cash flow of -$669.3M (-40.9% YoY). On the balance sheet, PCVX closed FY2025 with $3.00B in total assets against $142.7M in total debt (Altman Z-Score: 18.11, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$766.6K | -$655.6M | -$669.3M | $3.00B | $142.7M |
| FY2024 (FY) | 2024-12-31 | $0 | -$463.9K | -$452.6M | -$475.1M | $3.51B | $92.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$402.3K | -$296.8M | -$296.8M | $5.42B | $1.27B |
As of 2026-11-02, Vaxcyte Inc. (NASDAQ: PCVX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $62.03 (-0.93% 1D, market cap $9.85B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, PCVX ranks #303 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PCVX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.6%. By comparison, KRYS (Krystal Biotech Inc.) holds a B grade (72/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.61B) and KYMR (Kymera Therapeutics Inc.) posts a D grade (50/100 RQD, P/E 32.7x, ROIC -21.4%, cap $10.19B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
Per PCVX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649094), Vaxcyte Inc. generated $0 in revenue, -$766.6K in net income, and -$669.3M in free cash flow against $3.00B in total assets and $142.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PCVX last traded at $62.03 (-0.93% on volume of 1,714,650 shares), positioning the stock +0.67% above its 50-day simple moving average ($61.62) and +8.46% above its 200-day simple moving average ($57.19). Across its 52-week range of $39.87 to $90.75, PCVX sits at the 43.6% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($55.39 to $68.67).
Why PCVX Stock slipped -0.93% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PCVX scores 49 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 5 of 20 (ROIC -27.6%; FCF yield -6.79%), indicating the weakest contribution to the score. Whale/13F Flow scores 12 of 20 (institutional accumulation and options positioning), Insider Conviction scores 6 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 10 of 20 (Beta 1.07; sector sensitivity), and Forensic Balance Sheet scores 16 of 20 (Altman Z 18.11; Piotroski F 4/9; Debt/Equity 0.05).
For a prospective investor, the pattern is that the balance sheet is the strongest pillar while the cash-generation and insider-conviction pillars are weak. Negative ROIC and negative FCF yield mean the business is not currently converting capital into cash returns, so any upside case depends on future catalysts rather than present earnings power. The positive institutional and options signal offsets part of the weakness but does not change the overall distribution-warning verdict. Valuation tradeoffs are visible in the forward P/E of 23 alongside zero trailing EPS, meaning the price relies on expectations not yet reflected in reported earnings.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-923.7M | $-0.8M | N/A | $-669.3M | $174.0M | $142.7M |
| FY 2024 | $0.0M | $-569.5M | $-0.5M | N/A | $-475.1M | $387.9M | $92.5M |
| FY 2023 | $0.0M | $-468.0M | $-0.4M | N/A | $-296.8M | N/A | $1268.2M |
Per the SEC financials, the company reported no revenue across the three periods and operating losses that widened from $-468.0M in FY 2023 to $-923.7M in FY 2025. Per the market data, operating margin is -33.5%, gross margin and net margin are 0%, and ROIC is -27.6%. Per the Roarable RQD rating, the Altman Z-Score is 18.11, the Piotroski F-Score is 4/9, and Debt/Equity is 0.05, indicating a balance sheet with low leverage despite negative operating cash flow.
Per the recent news feed, the most prominent headline reports the closing of a $1.15 Billion public offering of common stock, pre-funded warrants, and convertible senior notes, including full exercise of underwriters' options. Per the same feed, Guggenheim raised its price target following a vaccine trial win (flagged GREEN), and the stock was reported to hit a new 52-week high. Other items include Investor's Business Daily coverage comparing the company to Pfizer and Merck in a $7 Billion market, and a Seeking Alpha note titled "Vaccine Titan In The Making."
Risk watch items: the $1.15 Billion financing is a dilution and capital-raise event relevant to the negative FCF and the $-669.3M FY 2025 free cash flow. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Vaxcyte Inc. (PCVX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.
Welcome to the PCVX (Vaxcyte Inc.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PCVX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Vaxcyte Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PCVX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $62.61 (52-wk range $39.87 - $90.75), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).